# Mivelsiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mivelsiran

> The next catalyst for mivelsiran, sponsored by ALNYLAM PHARMACEUTICALS, INC. (ALNY), is its topline data readout, May to Aug 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mivelsiran |
| Codes |  |
| Sponsor | ALNYLAM PHARMACEUTICALS, INC. (ALNY) https://sec-api.dev/companies/alny/catalysts |
| Indications | [early-onset ad, and in april 2023 and july 2023, we reported positive interim results](https://sec-api.dev/indications/early-onset-ad-and-in-april-2023-and-july-2023-we-reported-positive-interim-resu), caa and in july 2026, we, [Down Syndrome-Associated Alzheimer's Disease (DS-AD)](https://sec-api.dev/indications/down-syndrome-associated-alzheimer-s-disease-ds-ad) |
| Modality | sirna |
| FDA designations | none disclosed |

## Timeline

### Apr 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: early-onset AD, and in April 2023 and July 2023, we reported positive interim results.
- First seen 2025-02-13, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007497): "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results from the ongoing single ascending dose part of the Phase 1 clinical trial." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Apr 2023: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1. Indication: early-onset AD, and in April 2023 and July 2023, we reported positive interim results.
- First seen 2025-02-13, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007497): "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In early 2022, we initiated a Phase 1 clinical trial of mivelsiran in patients with early-onset AD, and in April 2023 and July 2023, we reported positive interim results from the ongoing single ascending dose part of the Phase 1 clinical trial." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Jul 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: CAA and in July 2026, we.
- First seen 2025-02-13, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001178670-26-000076): "In July 2024, we initiated the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA and in July 2026, we announced that we had completed enrollment in this trial." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm
- SEC Form 10-Q (accession 0001178670-26-000062): "In July 2024, we initiated the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA and in July 2026, we announced that we had completed enrollment in this trial." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028605): "In July 2024, we initiated the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007497): "In July 2024, we initiated the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-K (accession 0001628280-26-007497): "In July 2024, we announced we had initiated dosing in cAPPricron-1, a phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-047345): "In July 2024, we initiated dosing in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm
- SEC Form 10-Q (accession 0001178670-25-000090): "In July 2024, we initiated dosing in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm
- SEC Form 10-Q (accession 0001178670-25-000052): "In July 2024, we initiated dosing in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In July 2024, we initiated dosing in the cAPPRicorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In July 2024, we initiated dosing in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with CAA." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-13, last confirmed 2026-04-30.
- SEC Form 10-Q (accession 0001628280-25-047345): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm
- SEC Form 10-Q (accession 0001178670-25-000090): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm
- SEC Form 10-Q (accession 0001178670-25-000052): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm
- SEC Form 10-K (accession 0001178670-25-000026): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "We also expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-Q (accession 0001628280-26-028605): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007497): "We expect to initiate a Phase 2 clinical trial of mivelsiran in patients with AD in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Down Syndrome-Associated Alzheimer's Disease (DS-AD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07636811 (A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT07636811

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Down Syndrome-Associated Alzheimer's Disease (DS-AD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07636811 (A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT07636811

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mivelsiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mivelsiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mivelsiran

```bibtex
@misc{secapidev_pdufa_mivelsiran_20261116,
  title        = {Mivelsiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mivelsiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mivelsiran_20261116","title":"Mivelsiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mivelsiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
